Skip to main content

Table 2 Reduction in cell viability of MPM cells after incubation with Mapatumumab or Lexatumumab monoclonal antibodies. The percentage of reduction in cell viability was measured after incubation with 10 μg/ml Mapatumumab (Mapa) or Lexatumumab)Lexa) monoclonal antibodies. Data are expressed as mean ± s.d. from five independent experiments. **, P < 0.01 and *, P < 0.05 compared to untreated cells

From: Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin

  Reduction in cell viability (%) induced by
MPM cell lines 10 μg/ml Mapa 10 μg/ml Lexa
Mapa and Lexa resistant (< 20% cell death)   
H2052 3 ± 11 2 ± 9
SPC212 9 ± 5 * 7 ± 8
H226 5 ± 11 4 ± 6
more sensitive to Lexa   
ZL5 9 ± 3 ** 77+11 **
H2452 7 ± 3 ** 52 ± 7 **
SDM4 9 ± 9 36 ± 9 **
SDM6 14 ± 14 37 ± 14 *
ZL34 8 ± 5 * 21 ± 10 **
SDM13 13 ± 3 * 22 ± 1 **
more sensitive to Mapa   
H28 83 ± 2 ** 66 ± 20 *
MSTO-211H 48 ± 6 ** 24 ± 11 *
with similar sensitivity to Mapa and Lexa   
SPC111 33 ± 14 ** 31 ± 11 **
ZL55 31 ± 6 ** 30 ± 9 **